Paul Hampel, MD, Mayo Clinic, Rochester, MN, talks on the incorporation of molecular biomarkers in the treatment and management of chronic lymphocytic leukemia (CLL). Specifically, Dr Hampel discusses the use of fluorescence in situ hybridization (FISH) to detect 17p deletion, as well as other mutations. Dr Hampel comments on how such molecular biomarkers can aid in guiding prognostic discussions with the patient and can inform treatment decisions, particularly in determining eligibility for early intervention studies. Moreover, the future incorporation of next-generation sequencing (NGS) into routine clinical practice to detect tumor mutational load (TML) in patients is discussed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.